Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 8/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764244 | 0.96 | LMNA (0.52) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL9961983 | 0.94 | TP53 (0.50) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL9962000 | 0.93 | LMNA (0.54) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL764226 | 0.93 | LMNA (0.51) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL765020 | 0.93 | TP53 (0.52) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL8404029 | 0.93 | LMNA (0.51) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL9962170 | 0.92 | LMNA (0.50) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL763442 | 0.92 | LMNA (0.51) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL3340484 | 0.92 | LMNA (0.53) | LMNASTAT3TP53MAPTSMN1; SMN2 | |
| SCHEMBL11912507 | 0.91 | TP53 (0.52) | LMNASTAT3TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871375-B1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PTC THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |